Parvovirus B19 Infection Medication

  • Author: David J Cennimo, MD, FACP, FAAP, AAHIVS; Chief Editor: Russell W Steele, MD   more...
 
Updated: Mar 30, 2012
 

Medication Summary

No antiviral therapy is available to treat parvovirus B19 (B19V) infections. Children rarely require specific therapy other than acetaminophen for fever.

In patients with postinfectious arthritis, acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs) usually provide symptomatic relief. Because the use of aspirin in children with other viral illnesses has been associated with Reye syndrome, aspirin use is not recommended in children with B19V infection. If children have pruritus from the parvovirus B19 rash, oral antihistamines (eg, diphenhydramine) and starch baths typically provide relief.

Next

Antipyretic agents

Class Summary

These agents decrease or eliminate fever by acting at the level of the hypothalamus (acetaminophen) or by decreasing the activity of the enzyme cyclooxygenase, thereby decreasing the production of prostaglandins (NSAIDs).

View full drug information

Acetaminophen (Tylenol, Feverall, Tempra, Aspirin Free Anacin, Panadol)

 

Reduces fever by acting directly on hypothalamic heat-regulating centers, which increases dissipation of body heat via vasodilation and sweating.

View full drug information

Ibuprofen (Motrin, Ibuprin, Advil)

 

One of the few NSAIDs indicated for reduction of fever.

Previous
Next

Immunologic effectors

Class Summary

These agents are purified preparations of gamma globulin. Immunologic effectors are derived from large pools of human plasma and comprise 4 subclasses of antibodies, approximating the distribution of human serum.

Immunity to B19V infection appears to be purely humoral (ie, mediated via immunoglobulins). The role, if any, that cell-mediated immunity plays in providing immunity to B19V is unknown. As a result of the high seroprevalence of IgG against parvovirus among adults in the general population who have recovered from infection, the antiparvovirus IgG titer in IVIG is probably sufficient to provide passive immunity for the clearance of virus in immunocompromised hosts with chronic B19V infection.

View full drug information

Immune globulin, intravenous (Gammagard S/D, Carimune NF, Gammar-P)

 

Provides passive immunization against a broad spectrum of infectious agents. Neutralizes circulating myelin antibodies through anti-idiotypic antibodies; down-regulates proinflammatory cytokines, including INF-gamma; blocks Fc receptors on macrophages; suppresses inducer T and B cells and augments suppressor T cells; blocks complement cascade; promotes remyelination; may increase CSF IgG (10%).

Previous
Next

Antihistamines

Class Summary

These agents decrease or prevent allergic symptoms caused by histamine receptors from mast cells.

View full drug information

Diphenhydramine (Benadryl)

 

First-generation antihistamine that binds to H1 receptors in the CNS and the body.

Competitively blocks histamine from binding to H1 receptors. As a result of CNS penetration, diphenhydramine frequently causes drowsiness. A small percentage of children paradoxically respond to diphenhydramine with agitation.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

David J Cennimo, MD, FACP, FAAP, AAHIVS  Assistant Professor of Medicine and Pediatrics, Adult and Pediatric Infectious Diseases, Co-Director Physician's Core, University of Medicine and Dentistry of New Jersey-New Jersey Medical School

David J Cennimo, MD, FACP, FAAP, AAHIVS is a member of the following medical societies: American Academy of HIV Medicine, American Academy of Pediatrics, American College of Physicians, American Medical Association, HIV Medicine Association of America, Infectious Diseases Society of America, Medical Society of New Jersey, and Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

Coauthor(s)

Arry Dieudonne, MD  Associate Professor of Pediatrics, Division of Pulmonology, Allergy, Immunology and Infectious Diseases, University of Medicine and Dentistry of New Jersey-New Jersey Medical School; Clinical Director, Francois-Xavier Bagnold Center for Children, University Hospital

Arry Dieudonne, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, and Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Glenn Fennelly, MD, MPH  Director, Division of Infectious Diseases, Lewis M Fraad Department of Pediatrics, Jacobi Medical Center; Clinical Associate Professor of Pediatrics, Albert Einstein College of Medicine

Glenn Fennelly, MD, MPH is a member of the following medical societies: Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Joseph Domachowske, MD  Professor of Pediatrics, Microbiology and Immunology, Department of Pediatrics, Division of Infectious Diseases, State University of New York Upstate Medical University

Joseph Domachowske, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Society for Microbiology, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Robert W Tolan Jr, MD  Chief, Division of Allergy, Immunology and Infectious Diseases, The Children's Hospital at Saint Peter's University Hospital; Clinical Associate Professor of Pediatrics, Drexel University College of Medicine

Robert W Tolan Jr, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, Phi Beta Kappa, and Physicians for Social Responsibility

Disclosure: Novartis Honoraria Speaking and teaching

Chief Editor

Russell W Steele, MD  Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association

Disclosure: Nothing to disclose.

Additional Contributors

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous coauthor Dennis Cunningham, MD, to the original writing and development of this article.

References

  1. Cossart YE, Field AM, Cant B et al. Parvovirus-like particles in human sera. Lancet. 1975;1:72.

  2. Young NS, Brown KE. Parvovirus B19. N Engl J Med. Feb 5 2004;350(6):586-97. [Medline].

  3. Pattison JR,Jones SE, Hodgson J et al. Parvovirus infections and hypoplastic crisis in sickle cell anaemia. Lancet. 1981;1:664.

  4. Serjeant GR, Topley JM, Mason K, Serjeant BE, Pattison JR, Jones SE, et al. Outbreak of aplastic crises in sickle cell anaemia associated with parvovirus-like agent. Lancet. Sep 19 1981;2(8247):595-7.

  5. Cherry JD, Schulte DJ. Human Parvovirus B19. In: Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL, eds. Feigin & Cherry's Textbook of Pediatric Infectious Diseases. Vol 2. 6th ed. Philadelphia, PA: Saunders Elsevier; 2009:1902-1920.

  6. Servey JT, Reamy BV, Hodge J. Clinical presentations of parvovirus B19 infection. Am Fam Physician. Feb 1 2007;75(3):373-6. [Medline].

  7. Anderson LJ, Hurwitz ES. Human parvovirus B19 and pregnancy. Clin Perinatol. 1988;15:273.

  8. Brown KE. Parvovirus B19. In: Mandell GL, Bennet JE, Dolin R. Mandell, Douglas and Bennett's Principals and Practice of Infectious Diseases. Vol 2. 6th ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2005:1891-1902.

  9. American Academy of Pediatrics Committee on Infectious Diseases. Parvovirus B19. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. 2009 Red Book: Report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL: American Academy of Peiatrics; 2009:491-493.

  10. Brown KE. Human Parvoviruses. In: Long SS, Pickering LK, Prober CG, eds. Principles and Practice of Pediatric Infectious Diseases. 3rd ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2008:1072-1076.

  11. Burns K, Parish CR. Parvoviridae. In: Knipe DM, Howley PM, eds. Fields Virology. Vol 2. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007:65.

  12. Mustafa MM, McClain KL. Diverse hematologic effects of parvovirus B19 infection. Pediatr Clin North Am. Jun 1996;43(3):809-21. [Medline].

  13. Ergaz Z, Ornoy A. Parvovirus B19 in pregnancy. Reprod Toxicol. May 2006;21(4):421-35. [Medline].

  14. Luzzi GA, Kurtz JB. Human parvovirus arthropathy and rheumatoid factor(Letter). Lancet. 1985;1:1218.

  15. Conrad ME, Studdard H et al. Case report: aplastic crisis in sickle cell disorders: bone marrow necrosis and human parvovirus infection. Am J Med Sci. 1988;295:212.

  16. Eid AJ, Brown RA, Patel R, Razonable RR. Parvovirus B19 infection after transplantation: a review of 98 cases. Clin Infect Dis. Jul 1 2006;43(1):40-8. [Medline].

  17. Lindblom A, Heyman M, Gustafsson I, Norbeck O, Kaldensjo T, Vernby A. Parvovirus B19 infection in children with acute lymphoblastic leukemia is associated with cytopenia resulting in prolonged interruptions of chemotherapy. Clin Infect Dis. Feb 15 2008;46(4):528-36. [Medline].

  18. Young NS. Hematologic and hematopoietic consequences of B19 parvovirus infection. Semin Hematol. 1988;25:159.

  19. Mendelson E, Aboudy Y, Smetana Z, Tepperberg M, Grossman Z. Laboratory assessment and diagnosis of congenital viral infections:Rubella, cytomegalovirus (CMV), varicella-zoster virus (VZV),herpes simplex virus (HSV), parvovirus B19 andhuman immunodeficiency virus (HIV). Reprod Toxicol. 2006;21:350-382.

  20. Adler SP, Koch WC. Human Parvovirus Infections. In: Remington JS, Klein JO, Wilson CB, Baker CJ. Infectious Diseases of the Fetus and Newborn Infant. 6th ed. Philadelphia, PA: Saunders Elsevier; 2006:868-892.

  21. Tolfvenstam T, Broliden K. Parvovirus B19 infection. Semin Fetal Neonatal Med. Aug 2009;14(4):218-21. [Medline].

  22. Simms RA, Liebling RE, Patel RR, et al. Management and outcome of pregnancies with parvovirus B19 infection over seven years in a tertiary fetal medicine unit. Fetal Diagn Ther. 2009;25(4):373-8. [Medline].

  23. Infections. In: Cunningham FG, Leveno KL, Bloom SL, Hauth JC, Gilstrap III LC, Wenstrom KD, eds. Williams Obstetrics. 22nd Ed. USA: McGraw-Hill; 2001:chap 58.

  24. Broliden K, Tolfvenstam T, Norbeck O. Clinical aspects of parvovirus B19 infection. Jrnl Internal Med. 2006;260:285-304.

  25. Grilli R, Izquierdo MJ, Farina MC, et al. Papular-purpuric "gloves and socks" syndrome: polymerase chain reaction demonstration of parvovirus B19 DNA in cutaneous lesions and sera. J Am Acad Dermatol. Nov 1999;41(5 Pt 1):793-6. [Medline].

  26. Fretzayas A, Douros K, Moustaki M, Nicolaidou P. Papular-purpuric gloves and socks syndrome in children and adolescents. Pediatr Infect Dis J. Mar 2009;28(3):250-2. [Medline].

  27. Tschope C, Bock CT, Kasner M, Noutsias M, Westermann D, Schwimmbeck PL. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation. Feb 22 2005;111(7):879-86. [Medline].

  28. Douvoyiannis M, Litman N, Goldman DL. Neurologic manifestations associated with parvovirus B19 infection. Clin Infect Dis. Jun 15 2009;48(12):1713-23. [Medline].

  29. Kleinman SH, Glynn SA, Lee TH, et al. A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion. Blood. Oct 22 2009;114(17):3677-83. [Medline].

  30. Bredl S, Plentz A, Wenzel JJ, Pfister H, Möst J, Modrow S. False-negative serology in patients with acute parvovirus B19 infection. J Clin Virol. Jun 2011;51(2):115-20. [Medline].

  31. Soderlund-Venermo M, Hokynar K, Nieminen J et al. Persistence of human parvovirus B 19 in human tissues. 2002;50;:307-316.

  32. Musiani M, Zerbini M et al.Gentilomi G et al. Parvovirus B19 clearance from peripheral blood after acute infection. J Infect Dis. 1995;172:1360-1363.

  33. Anderson MJ, Higgins PG, Davis LR, Willman JS, Jones SE, Kidd IM. Experimental parvoviral infection in humans. J Infect Dis. Aug 1985;152(2):257-65. [Medline].

  34. Failey CK, Smoleniec JS et al. Observational study of effect of intrauterine transfusions on outcome of fetal hydrops after parvovirus B 19 infection. Lancet. 1995;346:1335-1337.

  35. [Guideline] Center for Disease control and Prevention. Risk associated with human parvovirus infection. MMWR. 1989;38:81.

  36. de Jong EP, Walther FJ, Kroes AC, Oepkes D. Parvovirus B19 infection in pregnancy: new insights and management. Prenat Diagn. May 2011;31(5):419-25. [Medline].

 
Previous
Next
 
Note the right side of this boy's face displaying signs of erythema infectiosum, or Fifth disease. Image courtesy of CDC
Elementary school child with Fifth Disease. Image courtesy of CDC.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.